- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01301235
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy
April 27, 2012 updated by: Amy Fleischman, MD, Massachusetts General Hospital
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics of the Vastus Lateralis After Sub-maximal Exercise in Patients With Mitochondrial Myopathy
This is a developmental protocol to determine the MRI based 31P-MRS changes seen in subjects with mitochondrial myopathy using our dynamic exercise protocol and to identify the ideal variable(s) to represent mitochondrial function.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
8
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Adults with mitochondrial disease
Description
Inclusion Criteria:
- Men and women ≥ age 18 years old with primary mitochondrial myopathy
- Known alteration in electron transport chain activity (<25 % activity of ETC) or known mutations in mitochondrial gene.
Exclusion Criteria:
Failure based on standard clinical MRI Screening form - the form is intended to establish the safety of subjects participating in the MRI scan without divulging any confidentiality information -
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Subjects with mitochondrial disease
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
PCr recovery after submaximal exercise by 31P-MRS
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2011
Primary Completion (ACTUAL)
November 1, 2011
Study Completion (ACTUAL)
April 1, 2012
Study Registration Dates
First Submitted
February 18, 2011
First Submitted That Met QC Criteria
February 18, 2011
First Posted (ESTIMATE)
February 23, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
April 30, 2012
Last Update Submitted That Met QC Criteria
April 27, 2012
Last Verified
April 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010P002441
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mitochondrial Disease
-
Stealth BioTherapeutics Inc.CompletedPrimary Mitochondrial DiseaseUnited States
-
Stealth BioTherapeutics Inc.TerminatedPrimary Mitochondrial DiseaseUnited States
-
Children's Hospital of PhiladelphiaUniversity of Pennsylvania; United Mitochondrial Disease Foundation (UMDF)Recruiting
-
Minovia Therapeutics Ltd.Not yet recruiting
-
University Hospital, BordeauxRecruiting
-
Stealth BioTherapeutics Inc.Active, not recruitingMitochondrial Diseases | Mitochondrial Myopathies | Mitochondrial Complex I Deficiency | Mitochondrial Pathology | Mitochondrial DNA Depletion | Mitochondrial DNA Mutation | Mitochondrial DNA Deletion | Mitochondrial Metabolism DefectSpain, United States, Italy, Netherlands, Australia, Germany, Hungary, New Zealand, Norway, United Kingdom
-
Newcastle-upon-Tyne Hospitals NHS TrustNewcastle UniversityCompleted
-
Rigshospitalet, DenmarkUniversity of CopenhagenRecruitingMitochondrial Diseases | Mitochondrial Myopathies | Mitochondrial DisorderDenmark
-
Radboud University Medical CenterCompletedMitochondrial Disorders
-
Stealth BioTherapeutics Inc.CompletedPrimary Mitochondrial DiseaseUnited States, Spain, Germany, Australia, Canada, Denmark, Hungary, Italy, United Kingdom